Ngā hua rapu - Cai, Wei-Ping
- E whakaatu ana i te 1 - 10 hua o te 10
-
1
Falling down and following up mā Wang, Charles, Cai, Wei-Ping, Tucker, Joseph D., Li, Ling-Hua, Hu, Feng-Yu
I whakaputaina 2012Text -
2
Current antibody-based immunoassay algorithm failed to confirm three late-stage AIDS cases in China: case report mā Li, Yan, Zhao, Jin-Kou, Wang, Ming, Han, Zhi-Gang, Cai, Wei-Ping, Zheng, Bo-Jian, Xu, Hui-Fang
I whakaputaina 2010Text -
3
-
4
Epidemiological and Virological Characterizations of the 2014 Dengue Outbreak in Guangzhou, China mā Zhao, Hui, Zhang, Fu-Chun, Zhu, Qin, Wang, Jian, Hong, Wen-Xin, Zhao, Ling-Zhai, Deng, Yong-Qiang, Qiu, Shuang, Zhang, Yu, Cai, Wei-Ping, Cao, Wu-Chun, Qin, Cheng-Feng
I whakaputaina 2016Text -
5
HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort st... mā Zhang, Fujie, Zhu, Hao, Wu, Yasong, Dou, Zhihui, Zhang, Yao, Kleinman, Nora, Bulterys, Marc, Wu, Zunyou, Ma, Ye, Zhao, Decai, Liu, Xia, Fang, Hua, Liu, Jing, Cai, Wei-Ping, Shang, Hong
I whakaputaina 2014Text -
6
ICAM-1 controls development and function of ILC2 mā Lei, Ai-Hua, Xiao, Qiang, Liu, Gao-Yu, Shi, Kun, Yang, Qiong, Li, Xing, Liu, Yu-Feng, Wang, Hai-Kun, Cai, Wei-Ping, Guan, Yu-Juan, Gabrilovich, Dmitry I., Zhou, Jie
I whakaputaina 2018Text -
7
Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China mā Wu, Ya-Song, Zhang, Wei-Wei, Ling, Xue-Mei, Yang, Lian, Huang, Shao-Biao, Wang, Xi-Cheng, Wu, Hao, Cai, Wei-Ping, Wang, Min, Wang, Hui, Liu, Yan-Fen, He, Hao-Lan, Wei, Fei-Li, Wu, Zun-You, Zhang, Fu-Jie
I whakaputaina 2016Text -
8
Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open... mā Guo, Peng-Le, He, Hao-Lan, Chen, Xie-Jie, Chen, Jin-Feng, Chen, Xiao-Ting, Lan, Yun, Wang, Jian, Du, Pei-Shan, Zhong, Huo-Lin, Li, Hong, Liu, Cong, Li, Li-Ya, Hu, Feng-Yu, Tang, Xiao-Ping, Cai, Wei-Ping, Li, Ling-Hua
I whakaputaina 2021Text -
9
Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19 mā LI, Ling Hua, TU, Hong Wei, LIANG, Dan, WEN, Chun Yan, LI, An An, LIN, Wei Yin, HU, Ke Qi, HONG, Wen Shan, LI, Yue Ping, SU, Juan, ZHAO, San Tao, LI, Wei, YUAN, Run Yu, ZHOU, Ping Ping, HU, Feng Yu, TANG, Xiao Ping, KE, Chang Wen, KE, Bi Xia, CAI, Wei Ping
I whakaputaina 2021Text -
10
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, co... mā Su, Bin, Yao, Cheng, Zhao, Qing-Xia, Cai, Wei-Ping, Wang, Min, Lu, Hong-Zhou, Chen, Yuan-Yuan, Liu, Li, Wang, Hui, He, Yun, Zheng, Yu-Huang, Li, Ling-Hua, Chen, Jin-Feng, Yu, Jian-Hua, Zhu, Biao, Zhao, Min, Sun, Yong-Tao, Lun, Wen-Hui, Xia, Wei, Sun, Li-Jun, Dai, Li-Li, Jiang, Tai-Yi, Wang, Mei-Xia, Zheng, Qing-Shan, Peng, Hai-Yan, Wang, Yao, Lu, Rong-Jian, Hu, Jian-Hua, Xing, Hui, Shao, Yi-Ming, Xie, Dong, Zhang, Tong, Zhang, Fu-Jie, Wu, Hao
I whakaputaina 2020Text